期刊文献+

阿法替尼有关物质的UPLC法测定

Determination of the Related Substances of Afatinib by UPLC
原文传递
导出
摘要 建立了超高效液相色谱法测定阿法替尼中的有关物质。使用C_(18)色谱柱,以0.05 mol/L磷酸盐缓冲液(含5 mmol/L四丁基硫酸氢铵,用磷酸调至pH 5.5)∶乙腈为流动相,线性梯度洗脱,检测波长240 nm。阿法替尼及其8个有关物质均在0.005~1μg/ml范围内线性关系良好,8个有关物质的平均回收率分别为101.3%、98.7%、102.9%、101.0%、97.7%、99.5%、100.1%和99.9%,RSD分别为1.08%、1.53%、1.04%、0.78%、1.59%、2.07%、1.91%和1.46%。本法适用于阿法替尼有关物质的检查。 An UPLC method was established for the determination of the related substances in afatinib. A C18 column was used, with the mobile phase of 0.05 mol/L phosphate buffer solution (containing 5 mmol/L tetrabutylammonium hydrogen sulfate, adjusted to pH 5.5 with phosphoric acid) : acetonitrile by linear gradient elufion, at the detection wavelength of 240 nm. The calibration curves of afatinib and its eight related substances were linear in the range of 0.005-1 μg/ml. The recoveries of 8 related substances were 101,3%, 98.7%, 102.9%, 101,0%, 97.7%, 99.5%, 100,1% and 99.9%, with RSDs of 1.08%, 1.53%, 1.04%, 0.78%, 1.59%, 2.07%, 1.91% and 1,46%, respectively. The established method is suitable for the quality control of afatinib.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2017年第10期1484-1488,共5页 Chinese Journal of Pharmaceuticals
关键词 阿法替尼 有关物质 超高效液相色谱 含量测定 afatinib related substance UPLC content determination
  • 相关文献

参考文献3

二级参考文献83

  • 1Jemal A,Murray T,Samuels A. Cancer statistics[J].CA:A Cancer Journal for Clinicians,2003,(01):5-26.doi:10.3322/canjclin.53.1.5.
  • 2Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anti-cancer agents[J].Drugs,2000,(01):1-14,41-42.doi:10.1517/14728220903540265.
  • 3Sibilia M,Kroismayr R,Lichtenberger BM. The epidermal growth factor receptor:from development to tumorigenesis[J].Differentiation,2007,(09):770-787.doi:10.1111/j.1432-0436.2007.00238.x.
  • 4Hirsch FR,Varella-Garcia M,Cappuzzo F. Predictive value of EGFR and HER2 over -expression in advanced non-small-cell lung cancer[J].Oncogene,2009,(Suppl1):S32-S37.
  • 5Kancha RK,von Bubnoff N,Peschel C. Functional analysis of epidermal growth factor receptor(EGFR)mutation and potential implications for EGFR targeted therapy[J].Clinical Cancer Research,2009,(2):460-467.doi:10.1158/1078-0432.CCR-08-1757.
  • 6Gazdar AF. Activating and resistance mutations of EGFR in non-small cell lung cancer:role in clinical response to EGFR tyrosine kinase inhibitors[J].Oncogene,2009,(suppl1):S24-S31.doi:10.1038/onc.2009.198.
  • 7Sibilia M,Kroismayr R,Lichtenberger BM. The epidermal growth factor receptor:from development to tumorigenesis[J].Differentiation,2007,(09):770-787.doi:10.1111/j.1432-0436.2007.00238.x.
  • 8Riely GJ,Pao W,Pham D. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib[J].Clinical Cancer Research,2006,(3 Pt 1):839-844.
  • 9Leidner RS,Fu P,Clifford B. Genetic abnormalities of the EGFR pathway in African American patients with non-small-cell lung cancer[J].Journal of Clinical Oncology,2009,(33):5620-5626.doi:10.1200/JCO.2009.23.1431.
  • 10Wissner A,Mansour TS. The development of HKI-272 and related compounds for the treatment of cancer[J].Archiv der Pharmazie,2008,(8):465-477.doi:10.1002/ardp.200800009.

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部